Cooperation between MYC and β-catenin in liver tumorigenesis requires Yap/Taz
Preprint
- 25 October 2019
- preprint
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 819631
Abstract
Background & Aims: Activation of MYC and CTNNB1 (encoding β-catenin) can co-occur in liver cancer, but how these oncogenes cooperate in tumorigenesis remains unclear.Approach & Results: We generated a mouse model allowing conditional activation of MYC and WNT/β-catenin signaling (through either β-catenin activation or Apc loss) upon expression of CRE recombinase in the liver, and monitored their effects on hepatocyte proliferation, apoptosis, gene expression profiles and tumorigenesis. Conditional activation of WNT/β-catenin signaling strongly accelerated MYC-driven carcinogenesis in the mouse liver. Both pathways also cooperated in promoting cellular transformation in vitro, demonstrating their cell-autonomous action. Short-term induction of MYC and β-catenin in hepatocytes followed by RNA-seq profiling allowed the identification of a “Myc/β-catenin signature”, composed of a discrete set of Myc-activated genes whose expression increased in presence of active β-catenin. Notably this signature enriched for targets of Yap and Taz, two transcriptional co-activators known to be activated by WNT/β-catenin signaling, and to cooperate with MYC in mitogenic activation and liver transformation. Consistent with these regulatory connections, Yap/Taz accumulated upon Myc/β-catenin activation and were required not only for the ensuing proliferative response, but also for tumor cell growth and survival. Finally, the Myc/β-catenin signature was enriched in a subset of human hepatocellular carcinomas characterized by comparatively poor prognosis.Conclusions: Yap and Taz mediate the cooperative action of Myc and β-catenin in liver tumorigenesis. This warrants efforts toward therapeutic targeting of Yap/Taz in aggressive liver tumors marked by elevated Myc/β-catenin activity.Keywords
All Related Versions
- Published version: Hepatology, 72 (4), 1430.
This publication has 63 references indexed in Scilit:
- Comprehensive and Integrative Genomic Characterization of Hepatocellular CarcinomaCell, 2017
- Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic ModalitiesCell, 2017
- Genetic Landscape and Biomarkers of Hepatocellular CarcinomaGastroenterology, 2015
- Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targetsNature Genetics, 2015
- A Critical Role for the Regulated Wnt–Myc Pathway in Naive T Cell SurvivalThe Journal of Immunology, 2014
- B-catenin deficiency, but not Myc deletion, suppresses the immediate phenotypes of APC loss in the liverProceedings of the National Academy of Sciences, 2008
- Myc deletion rescues Apc deficiency in the small intestineNature, 2007
- Wnt/β-catenin signaling acts upstream of N-myc, BMP4, and FGF signaling to regulate proximal–distal patterning in the lungDevelopmental Biology, 2005
- Liver-targeted disruption ofApcin mice activates β-catenin signaling and leads to hepatocellular carcinomasProceedings of the National Academy of Sciences, 2004
- Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomasProceedings of the National Academy of Sciences, 1998